Daniel Allen, DO
Family Medicine · Middleton, IDNPI 1720017247
Payments from drug & device makers
Across 370 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$991
- AstraZeneca$625
- Amgen$423
- Pfizer$392
- AbbVie$382
- Sunovion Pharmaceuticals Inc.$312
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,15096%
- Education$2174%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 99 | $991 |
| AstraZeneca | 43 | $625 |
| Amgen(2 entities) | 20 | $423 |
| Pfizer | 29 | $392 |
| AbbVie(2 entities) | 20 | $382 |
| Sunovion Pharmaceuticals Inc. | 25 | $312 |
| Astellas Pharma US Inc | 18 | $257 |
| Teva Pharmaceuticals USA, Inc. | 5 | $243 |
| Johnson & Johnson | 15 | $202 |
| Lilly USA, LLC | 12 | $181 |
| Novartis | 9 | $161 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $111 |
| Bayer | 6 | $93 |
| Acadia Pharmaceuticals Inc | 6 | $90 |
| Grifols USA, LLC | 5 | $88 |
| Merck | 5 | $76 |
| Sanofi-aventis U.S. LLC | 5 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Avanir Pharmaceuticals, Inc. | 4 | $60 |
| Amarin Pharma, Inc. | 3 | $55 |
| Nestle Healthcare Nutrition Inc. | 3 | $52 |
| Boehringer Ingelheim | 2 | $42 |
| GSK | 3 | $41 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Biogen | 2 | $35 |
| Mylan Specialty L.p. | 2 | $33 |
| Adlon Therapeutics L.p. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Eisai Inc. | 2 | $26 |
| Abbott | 1 | $21 |
| Medtronic | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Organon | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Corcept Therapeutics | 1 | $12 |
How this compares
$5,368 in reported general payments places this provider in the 90th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 2,152 | $655,759 |
| TrulicityDulaglutide | 148 | $142,583 |
| JardianceEmpagliflozin | 405 | $132,967 |
| MyrbetriqMirabegron | 519 | $127,793 |
| OzempicSemaglutide | 120 | $122,917 |
| FarxigaDapagliflozin Propanediol | 380 | $115,206 |
| XareltoRivaroxaban | 358 | $96,085 |
| JanuviaSitagliptin Phosphate | 245 | $78,109 |
| AustedoDeutetrabenazine | 29 | $75,636 |
| OrenciaAbatacept | 12 | $72,213 |
| IngrezzaValbenazine Tosylate | 15 | $59,323 |
| Risperdal ConstaRisperidone Microspheres | 35 | $53,285 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $52,259 |
| RestasisCyclosporine | 110 | $49,214 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 730 | $46,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $392 | $693,6422,187 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $202 | $149,370393 claims |
| Lilly USA, LLCTrulicity | $181 | $142,583148 claims |
| Boehringer IngelheimJardiance | $42 | $132,967405 claims |
| Astellas Pharma US IncMyrbetriq | $257 | $127,793519 claims |
| Novo NordiskOzempic | $991 | $122,917120 claims |
| AstraZenecaFarxiga | $625 | $115,206380 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $41 | $83,879163 claims |
| MerckJanuvia | $76 | $78,109245 claims |
| AbbVieRestasis, Linzess | $382 | $76,738162 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $243 | $75,63629 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $37 | $59,32315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 803 family medicine providers in Idaho.
Other family medicine in Middleton
- William LaitinenMiddleton$1.1M
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Gary SoucieBlackfoot$5.8M
- Brock McConneheyBoise$4.5M
- Diane McConneheyBoise$681K
- Flint PackerIdaho Falls$587K
- Paul BeckettBlackfoot$344K
- Elaine DavidsonMeridian$303K
- Kenneth CongerSandpoint$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.